NASDAQ · ACHV
Achieve Life Sciences, Inc.
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
Loading market information…
NASDAQ · TRDA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Entrada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Entrada Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.98. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Entrada Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.42+46.15% vs estimate | $20.56M+110.4% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.03+104.55% vs estimate | $37.40M+185.04% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$0.35+47.76% vs estimate | $19.57M+51.43% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $14.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$6.63+$0.40 (+6.42%)
Capricor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.58% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$12.15+$0.08 (+0.66%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
$10.43-$0.31 (-2.89%)
Sagimet Biosciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.91% below the high.
$4.02+$0.03 (+0.75%)
Immuneering Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.59% below the high.
$4.05+$0.05 (+1.25%)
Vanda Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.26% below the high.
